Blog Archive
-
▼
2007
(88)
-
▼
August
(15)
- Needle-Free Drug Delivery Technology for Diabetes ...
- BodyTel Scientific to Exhibit the GlucoTel System ...
- Pfizer and Bristol-Myers Squibb Worldwide Collabor...
- Teijin and Chugai, agreement to co-develop Ipsen's...
- Cannasat Therapeutics, Commence Phase 1 Study of C...
- AtheroGenics , Phase III clinical trial of AGI-106...
- Blood Glucose Meter, Medtronic and LifeScan Annou...
- Sirtris Pharmaceuticals, SRT501 product candidate ...
- Blood Glucose Meter, Medtronic and Bayer Diabetes ...
- Novo Nordisk, Liraglutide improves glucose control
- Diabetic Neuropathic Pain, UCB's subsidiary SCHWAR...
- Oramed oral insulin gel capsule
- CombinatoRx CRx-401 for Type 2 Diabetes
- Avigen, Neuropathic Pain : Clinical Development fo...
- a news diabetes blog
-
▼
August
(15)
Friday, August 31, 2007
Needle-Free Drug Delivery Technology for Diabetes Drug, Anesiva Grants Specific-Use License to Particle Therapeutics
August 30, 2007— Anesiva, Inc. (Nasdaq: ANSV) and Particle Therapeutics Limited have entered into an agreement granting Particle Therapeutics a specific-use license to incorporate Anesiva’s drug delivery technology into its needle-free, intradermal delivery system for glucagon, a hormone commonly used for the treatment of hypoglycemia associated with Type 1 and Type 2 diabetes... Anesiva's Press Release - Particle Therapeutics' Press Release -
Libellés :
Anesiva,
Particle Therapeutics,
Type 1 Diabetes,
Type 2 Diabetes